Viatris Inc. (VTRS) FDA Accepts sNDA for Presbyopia Treatment with October PDUFA Date [Yahoo! Finance]
Viatris Inc. (VTRS)
Company Research
Source: Yahoo! Finance
Viatris Inc. (NASDAQ: VTRS ) is one of the most undervalued stocks under $30 to buy . On February 25, Viatris announced that the FDA accepted its sNDA for MR-141, which is a phentolamine ophthalmic solution 0.75% intended to treat presbyopia. The FDA set a PDUFA goal date of October 17 this year, to complete its review. Presbyopia is a nearly universal age-related condition that affects roughly 90% of US adults over 45, causing a progressive loss of near-focusing ability and impacting approximately 128 million people domestically. The application is supported by positive data from two pivotal Phase 3 trials, VEGA-2 and VEGA-3, which met all primary and key secondary endpoints without any treatment-related serious adverse events. Unlike some other treatments, MR-141 uses a physiological approach that relaxes the iris dilator muscle to improve near vision without affecting the ciliary muscle, thereby preserving distance vision. Detailed findings from the VEGA-3 trial are scheduled fo
Show less
Read more
Impact Snapshot
Event Time:
VTRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTRS alerts
High impacting Viatris Inc. news events
Weekly update
A roundup of the hottest topics
VTRS
News
- UBS and BofA Lift Price Targets on Viatris (VTRS) [Yahoo! Finance]Yahoo! Finance
- Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research [Yahoo! Finance]Yahoo! Finance
- GoodRx to offer up to 85% discount on Viatris drugs [Seeking Alpha]Seeking Alpha
- Viatris (VTRS): Buy, Sell, or Hold Post Q4 Earnings? [Yahoo! Finance]Yahoo! Finance
- Viatris (VTRS) Delivers Solid 2025 Growth and Robust Cash Flow at Deep Value [Yahoo! Finance]Yahoo! Finance
VTRS
Earnings
- 2/26/26 - Beat
VTRS
Sec Filings
- 3/10/26 - Form 4
- 3/10/26 - Form 4
- 3/10/26 - Form 4
- VTRS's page on the SEC website